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Abstract
Background: In recent years, microRNA (miRNA) pathways have emerged as a crucial system for the regulation of
tumorogenesis. miR-SNPs are a novel class of single nucleotide polymorphisms that can affect miRNA pathways.
Design and Methods: We analyzed eight miR-SNPs by allelic discrimination in 141 patients with Hodgkin lymphoma and
correlated the results with treatment-related toxicity, response, disease-free survival (DFS) and overall survival (OS).
Results: The KRT81 (rs3660) GG genotype was associated with an increased risk of neurological toxicity (P= 0.016), while
patients with XPO5 (rs11077) AA or CC genotypes had a higher rate of bleomycin-associated pulmonary toxicity (P= 0.048).
Both miR-SNPs emerged as independent factors in the multivariate analysis. The XPO5 AA and CC genotypes were also
associated with a lower response rate (P= 0.036). XPO5 (P= 0.039) and TRBP (rs784567) (P= 0.022) genotypes emerged as
prognostic markers for DFS, and XPO5 was also associated with OS (P= 0.033). In the multivariate analysis, only XPO5
emerged as an independent prognostic factor for DFS (HR: 2.622; 95%CI 1.039–6.620; P= 0.041). Given the influence of XPO5
and TRBP as individual markers, we then investigated the combined effect of these miR-SNPs. Patients with both the XPO5
AA/CC and TRBP TT/TC genotypes had the shortest DFS (P= 0.008) and OS (P= 0.008).
Conclusion: miR-SNPs can add useful prognostic information on treatment-related toxicity and clinical outcome in Hodgkin
lymphoma and can be used to identify patients likely to be chemoresistant or to relapse.
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Introduction
Hodgkin lymphoma (HL) is a highly curable B-cell neoplasm
characterized by the presence of a relatively small population of
malignant tumor cells, known as Hodgkin/Reed-Sternberg (HRS)
cells, in a non-neoplastic microenvironment [1]. As the neoplastic
HRS cells typically represent ,1% of the total infiltrate, crosstalk
between the non-neoplastic inflammatory cell infiltrate and the
HRS cells is an integral and important aspect of HL[2]. The
introduction of MOPP (mechlorethamine, vincristine, procarba-
zine, and prednisone) was a seminal event in the treatment of HL,
attaining complete response rates approaching 84% and long-term
disease-free survival (DFS) rates of approximately 66% [3]. Later,
however, ABVD (doxorubicin/bleomycin/vinblastine/dacarba-
zine) was shown to have a superior risk-to-benefit ratio, and
ABVD or MOPPABVD (MOPP alternating with ABVD) is now
the standard chemotherapy regimen for HL [4]. The treatment of
patients with HL is primarily guided by the clinical stage of
disease. Stage I–II patients are treated with chemotherapy, mainly
ABVD, followed by involved field radiotherapy [5]. In stages III–
IV, combination chemotherapy followed by consolidation radio-
therapy in selected patients is the standard treatment, with three
regimens: ABVD, escalated BEACOPP (bleomycin, etoposide,
doxorubicin, cyclophosphamide, vincristine, procarbazine, and
prednisone) and STANFORD V (doxorubicin, vinblastine,
mechlorethamine, vincristine, bleomycin, etoposide, and predni-
sone) [6]. While the majority of patients will be cured, treatment-
related toxicities are often a cause of late mortality. All three
regimens are associated with both acute and long-term toxicities,
including neutropenia, nausea/vomiting, sensory neuropathy,
bleomycin-associated pulmonary toxicity, and cardiomyopathy
[7]. Moreover, a non-negligible percentage (20%) of patients will
relapse or will be refractory after first-line treatment[8]. Biomark-
ers to accurately identify patients with a high risk of treatment
failure or recurrence would thus be a useful tool in the
management of HL.
In recent years, the microRNA (miRNA) pathway has emerged
as a crucial system for the regulation of tumorogenesis, where
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miRNAs can act as either tumor suppressor or oncogenes [9].
These small RNA molecules regulate numerous processes in the
tumor cell mainly by inhibiting the translation of multiple
messenger RNAs [10]. In HL, miRNA expression has been
assessed in lymph nodes [11], in microdissected HRS cells [12],
and in HL cell lines [13,14]. One of several deregulated miRNAs,
miR-135a, was shown to have prognostic significance [15].
miRNA expression is known to be deregulated in tumors due to
various mechanisms, such as chromosome alterations, mutations,
deletions, methylation or polymorphisms [16].
Single nucleotide polymorphisms (SNPs) are DNA variations
that occur when a single nucleotide in the genome sequence is
altered. Millions of SNPs have been catalogued in the human
genome, and their pattern in each individual can help explain the
development of disease and response to pathogens, chemicals,
drugs and vaccines [17], making them key enablers for person-
alized medicine [18]. SNPs related to the miRNA pathway, known
as miR-SNPs [19], can affect miRNA functions in different ways
depending on their location [20] – either by directly impacting
miRNA expression levels or by influencing the miRNA-target
interaction. SNPs in the promoter sequence of the miRNA gene
can alter its transcription, those in the pri- or pre-miRNA
sequence can influence miRNA maturation [21], and those
regulating the expression of proteins involved in miRNA
biogenesis can alter the miRNAome in the cell. SNPs in the
mature sequence of the miRNA or in the miRNA target sites are
both frequent and specific and can disrupt or alter the miRNA-
mediated repression of a target gene [22]. The study of miR-SNPs
thus opens a new area of research in cancer biology and clinical
oncology, especially as related to risk stratification, response to
therapy, and treatment-related toxicity.
SNPs in interleukin genes, DNA repair genes and metabolic
enzymes have been associated with risk [23], clinical outcome
[24,25] and treatment-related toxicities [26] in HL. miR-SNPs
have been related to clinical outcome in several solid tumors
[27,28] and in myeloma[29]. However, to the best of our
knowledge, the role of miR-SNPs in HL has not been investigated.
In the present work, we have assessed the presence of eight miR-
SNPs in HL patients and explored their potential as markers of
treatment-related toxicity and prognosis.
Results
Patients
Table 1 shows the main demographic and clinical character-
istics for all 141 patients. Median age was 32 years (range, 13–89)
and 51.1% were males. The majority (58.9%) had nodular
sclerosis. Epstein-Barr Virus was present in 38.1% of the samples.
First-line therapy consisted of ABVD in 52% of patients and
MOPPABVD in 38%. Median follow-up was 50 months (range,
1–143).
miR-SNPs, treatment related-toxicity and response
Table 2 shows the genotypic frequencies for all eight miR-SNPs
analyzed, both in the present study and as reported in the NCBI
SNP database (dbSNP) for the European population.
HWE, Hardy Weinberg equilibrium.
Among all 141 patients, 33.3% had neutropenia, 4.3% anemia,
4.3% thrombocytopenia, 5% bleomycin-associated pulmonary
toxicity, 16.3% neurological toxicity and 36.2% infectious-related
toxicity (Table 1). The results of the univariate analysis for the
association between treatment-related toxicities and clinical
characteristics are shown in Table S1. Patients harboring the
KRT81 GG genotype had a higher rate of neurological toxicity
than those with the CC or CG genotype (31% vs. 12%; P= 0.016).
Patients carrying the XPO5 AA or CC genotype had a higher
incidence of bleomycin-associated pulmonary toxicity than those
with the AC genotype (10% vs. 1%; P= 0.048).
The overall response rate was 89.4%, with 119 patients (84.4%)
who achieved complete response, 7 (5%) who showed a partial
response, and 14 (9.9%) non-responders. The overall response rate
dropped to 83% in patients harboring the XPO5 AA or CC
genotype but rose to 95.7% in those with the CC genotype
(P= 0.036).
In the multivariate analysis for neurological toxicity including
KRT81 genotype, treatment strategy (ABVD or MOPABV),
number of cycles of treatment (#4 cycles or.4 cycles) and all
clinical variables with P,0.2 in the univariate analysis (Table S1),
KRT81 GG genotype emerged as an independent risk factor (HR,
6.652; 95%CI, 1.330–33.262; P= 0.021), together with, ABVD
treatment strategy (HR, 0.056; 95%CI, 0.012–0.258; P,0.001)
and reduced number of cycles (HR, 0.045; 95%CI, 0.003–0.705;
P= 0.027) (Table 3). In the multivariate analysis for bleomycin-
associated pulmonary toxicity, including XPO5 genotype, treat-
ment strategy (ABVD or MOPABV), number of cycles of
treatment (#4 cycles or.4 cycles) and all clinical variables with
P,0.2 in the univariate analysis (Table S1), XPO5 AC genotype
emerged as an independent protective factor (HR, 0.49; 95%CI,
0.006–0.376; P= 0.004), together with ABVD treatment strategy
(HR, 0.197; 95%CI, 0.059–0.651; P= 0.008) (Table 3).
miR-SNPs, DFS and OS
Mean DFS was 106.6 months (95% CI, 96.2–117.1), and
median DFS was not reached. No clinical characteristics were
associated with DFS (Table 1). Of the eight miR-SNPs analyzed,
only TRBP and XPO5 genotypes were associated with DFS.
Mean DFS for 37 patients (31.6%) with the TRBP CC genotype
was 124 months (95% CI, 112–136) vs. 86.8 months (95% CI, 74–
89) for those with the TT or TC genotype (P= 0.022) (Figure 1A).
Mean DFS for 62 patients (56.3%) with the XPO5 AC genotype
was 114.2 months (95% CI, 101–127) vs. 85.8 months (95% CI,
68–104) for patients with the AA or CC genotype (P= 0.039)
(Figure 1B). A trend towards an association between the
MIR196A2 genotype and DFS was also observed; mean DFS
was 115 months (95% CI, 99–131) for patients with the CC
genotype, compared to 81 months (95% CI, 66–97) for those with
the CT or TT genotype (P= 0.07) (Figure 1C).
Mean OS was 126.6 months (95% CI, 118.6–134.6), and
median OS was not reached. Older age (P,0.001), histology other
than nodular sclerosis (P= 0.001), B-symptoms (P,0.001), anemia
(P,0.001), lymphocytopenia (P= 0.003), hypoalbuminemia
(P,0.001), high LDH level (P= 0.021), high B-2-microglobulin
level (P,0.001), and advanced stage (P,0.001) were associated
with shorter OS (Table 1). Of the eight miR-SNPs analyzed, only
XPO5 was associated with OS. Mean OS for 71 patients (54.2%)
with the XPO5 AC genotype was 135.3 months (95% CI, 127–
143) vs. 114.2 months (95% CI, 99–129) for those with the AA or
CC genotype (P= 0.033) (Figure 1D). Table S2 displays the clinical
characteristics of the HL patients stratified according to the miR-
SNPs analyzed.
Since prognosis in HL has been shown to differ between
patients,45 years old and those$45years old, we performed an
age-adjusted analysis of all miR-SNPs that showed significant
differences in the entire cohort. The effect of TRBP on DFS that
was observed in the entire cohort was maintained in both age
groups (Figure 1, Figure S1). In contrast, the effect of XPO5 and
MIR196A2 on DFS was maintained only in younger patients.
Finally, the benefit in OS observed in the entire cohort for patients
MiR-SNPs in HL
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heterozygous for XPO5 was also observed in both groups in the
age-adjusted analysis. (Table S3 and Figure S1).
miR-SNPs in early- and advanced-stage HL
Since treatment strategies in HL are different for early-stage
(Ann Arbor stage I and II) and advanced-stage (stage III and IV)
patients [38], we examined DFS and OS according to miR-SNPs
in each of these subgroups.
Mean DFS for early-stage patients was 104.6 months (95% CI,
94–115), and mean OS was 138.9 months (95% CI, 134.2–143.7).
DFS was 72.3 months (95% CI, 59–86) for patients with the
KRT81 CG genotype and 114.3 months (95% CI, 103–125) for
those with the TT or TC genotype (P= 0.037) (Figure 2A). A trend
towards an association between the TRBP genotype and DFS in
early-stage patients was also observed; mean DFS was 117 months
(95% CI, 105–129) for patients with the TT genotype, compared
Table 1. Patient characteristics and P-values for DFS and OS in the univariate analyses.
Characteristic Value
N= 141
N (%)
5 year DFS(%)
(DFS time range)
DFS
P-value
5 year OS(%)
(OS time range)
OS
P-value
Sex Male 72 (51.1) 71.1 (1 to 135) 0.817 88.9 (2 to 142.4)0.722
Female 69 (48.9) 79.3 (3 to 126) 87.4 (2 to 144)
Median age (range) 32 (13–89)
,45 110 (78) 77.9 (1 to 135) 0.100 95.7 (9 to 143) ,0.001
$45 31 (22) 64.7 (3 to 91) 61 (2 to119)
Histology Nodular sclerosis 83 (58.9) 77.2 (1 to 135) 0.478 95.1 (9 to 144) 0.001
Other 58 (41.1) 72.4 (1 to 106) 78.5 (2 to 120)
B symptoms Yes 59 (41.8) 69.4 (1 to 104) 0.470 75.6 (2 to 127) ,0.001
No 82 (58.2) 78.6 (3 to 135) 92.7 (11 to 144)
Bulky mass Yes 29 (20.6) 84.4 (4 to 111) 0.239 90.4 (11 to 0.298
No 112 (79.4) 72.8 (1 to 135) 127)
86.3 (2 to 144)
Anemia, Hb levels less than 105 g/L Yes 31 (22) 60 (1 to 77) 0.091 70.4 (2 to 127) ,0.001
No 110 (78) 79.2 (1 to 135) 93.4 (9 to 144)
Leukocytosis, more than 156109/L Yes 17 (12.1) 75 (2 to 82) 0.987 88.2 (10 to 92) 0.287
No 124 (87.9) 75.9 (1 to 135) 88.4 (2 to 144)
Lymphocytopenia, ,0.66109/L or
,8% of WBC
Yes 17 (12.1) 57.1 (1 to 78) 0.642 68.8 (2 to 119) 0.003
No 124 (87.9) 77.6 (1 to 135) 90.7 (2 to 144)
Hypoalbuminemia, ,40 g/L Yes 46 (32.6) 77.6 (1 to 126) 0.656 70.7 (2 to 142) ,0.001
No 86 (60.9) 73.2 (1 to 135) 94.3 (9 to 144)
High LDH level, .450 UI/L Yes 40 (28.4) 64.6 (1 to 106) 0.321 78.6 (2 to 119) 0.021
No 99 (70.2) 78.6 (1 to 135) 92.1 (2 to 144)
High B-2-microglobulin
level,.25 mg/L
Yes 27 (19.1) 73.1 (1 to 104) 0.974 68.2 (2 to 112) ,0.001
No 84 (60) 72.6 (1 to 135) 94.9 (9 to 144)
Stage early (I–II) 86 (61) 78.5 (1 to 126) 0.148 96.7 (3 to 142) ,0.001
advanced (III–IV) 54 (38.6) 68 (1 to 134) 74.2 (2 to 144)
EBV Positive 40 (38.1) 50.8 (1 to 90) 0.480 75 (2 to 106) 0.120
Negative 65 (46.1) 69.9 (1 to 90) 87.9 (2 to 100)
Unknown 36 (15.8)
Treatment ABVD 73 (52.1) 60.6 (1 to 109) 0.265 95.7 (2 to 116) 0.221
MOPPABV 53 (37.9) 77.9 (1 to 135) 86.1 (2 to 145)
MOPP 8 (5.7) 100 (26 to 120) 85.7 (3 to 142)
Other 7 (4.3) 25 (2 to 19)
Toxicities Neutropenia 47 (33.3) 77.9 (3 to 104) 0.473 79.6 (1–112) 0.018
Anemia 6 (4.3) 66.7(3 to 91) 0.375 33.3 (2 to 99) ,0.001
Thrombocytopenia 6 (4.3) 66.7 (3 to 91) 0.658 44.4 (2 to 99) 0.001
Pulmonary toxicity 7 (5) 68.6 (3 to 88) 0.464 85.7 (16 to106) 0.889
Neurological toxicity 23 (16.3) 71 (6 to 113) 0.729 95.2 (19 to135) 0.169
Infectious toxicity 51 (36.2) 80 (3 to 113) 0.375 80 (1 to 123) 0.019
doi:10.1371/journal.pone.0064716.t001
MiR-SNPs in HL
PLOS ONE | www.plosone.org 3 May 2013 | Volume 8 | Issue 5 | e64716
to 92 months (95% CI, 78–106) for those with the CC or TC
genotype (P= 0.081) (Figure 2B). Only two deaths occurred among
early-stage patients.
Mean DFS for advanced patients was 91.6 months (95%CI,
67.9–115.3), and mean OS was 101.4 months (95% CI, 82.2–
120.5). Only XPO5 was associated with DFS and OS. All patients
with the XPO5 AC genotype were disease-free at the time of this
Table 2. Genotypic frequencies in the present study and for the European Population (HapMap-CEU) in NCBI dbSNP.
Gene Genotype European population (%) Present study N* (%) HWE X2 (p-value)
MIR196A2 rs11614913 CC 33.6 61 (43.6) 0.04 (p = 0.838)
N=140 CT 44.2 62 (44.3)
TT 22.2 17 (12.1)
MIR149 rs2292832 CC 55 61 (58.7) 11.37 (p,0.001)
N=104 CT 36 28 (26.9)
TT 9 15 (14.4)
MIR423 rs6505162 AA 31 36 (32.7) 2.15 (p = 0.143)
N=110 AC 57.5 47 (42.7)
CC 11.5 27 (24.5)
MIR146A rs2910164 GG 59.3 73 (51.8) 0.41 (p = 0.521)
N=141 CG 34.5 59 (41.8)
CC 6.2 9 (6.4)
KRT81 rs3660 CC 36.7 32 (23.05) 0.75 (p = 0.387)
N=139 CG 45 64 (46.05)
GG 18.3 43 (30.9)
FAM179B rs1053667 TT 92.9 95 (92.2) 3.59 (p = 0.058)
N=103 CT 6.2 7 (6.8)
CC 0.9 1 (1)
XPO5 rs11077 AA 33.6 25 (19.7) 0.48 (p = 0.487)
N=127 AC 46 67 (52.8)
CC 20.4 35 (27.6)
TRBP rs784567 CC 23.9 40 (28.8) 0.04 (p = 0.837)
N=139 CT 54 68 (48.2)
TT 22.1 31 (22.3)
*In some cases the genotype could not be determined for technical reasons; ‘‘N’’ indicates the number of patients genotyped in each case.
doi:10.1371/journal.pone.0064716.t002
Table 3. Multivariate analyses for neurological toxicity and for bleomycin-associated pulmonary toxicity.
P Hazard Ratio 95% CI
Neurological Toxicity
ABVD treatment p,0.001 0.056 0.012–0.258
#4 cycles of treatment 0.027 0.045 0.003–0.705
Female 0.002 0.057 0.009–0.354
High LDH 0.625 1.458 0.322–6.602
EBV 0.322 1.913 0.530–6.902
KRT81 GG 0.021 6.652 1.330–33.262
Pulmonary toxicity
ABVD treatment 0.008 0.197 0.059–0.651
#4 cycles of treatment 0.998 0.000 0.00-.
Anemia 0.878 0.868 0.143–5.268
High B-2-microglobulin 0.660 1.446 0.280–7.460
XPO5 AC 0.004 0.49 0.006–0.376
doi:10.1371/journal.pone.0064716.t003
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analysis, while mean DFS among patients with the AA or CC
genotype was 30.9 months (95% CI, 18–44) (P= 0.002)
(Figure 2C). OS was 133 months (95% CI, 118–148) in patients
harboring the AC genotype compared to 74 months (95% CI, 55–
94) for those with the AA or CC genotype (P= 0.035) (Figure 2D).
When the false discovery rate was used to correct for multiple
comparisons, XPO5 maintained statistical significance (adjusted
P= 0.018).
TRBP and XPO5 miR-SNPs in combination
Given the evidence for the influence of TRBP and XPO5 as
individual markers, we then investigated the combined effect of
these miR-SNPs on DFS and OS. We found a significant
correlation between the TRBP/XPO5 combination and both
DFS and OS. Patients with both the XPO5 AA/CC and TRBP
TT/TC genotypes had the worst prognosis. DFS was 74 months
(95% CI, 54–94) for patients with the unfavorable combination,
compared to 114 months (95% CI, 102–126) for those with other
combinations (P= 0.008) (Figure 3A), while OS was 103 months
(95% CI, 86–120) for patients with the unfavorable combination
and 135 months (95% CI, 128–143) for those with other
combinations (P= 0.008) (Figure 3B). When the false discovery
rate was used to correct for multiple comparisons, the TRBP/
XPO5 combination maintained statistical significance (DFS,
adjusted P= 0.064; OS, adjusted P= 0.032).
Multivariate analyses
We performed independent multivariate analyses for DFS and
OS including all variables with a univariate P,0.2. In the analysis
for DFS, the XPO5 AA+CC genotype emerged as an independent
Figure 1. Clinical outcomes according to miR-SNPs. DFS according to TRBP, XPO5 and MIR196A2, and OS according to XPO5. (A) Mean DFS for
37 patients (31.6%) with the TRBP CC genotype was 124 months (95% CI, 112–136) vs. 86.8 months (95% CI, 74–89) for those with the TT or TC
genotype (P= 0.022). (B) Mean DFS for 62 patients (56.3%) with the XPO5 AC genotype was 114.2 months (95% CI, 101–127) vs. 85.8 months (95% CI,
68–104) for patients with the AA or CC genotype (P= 0.039). (C) A trend towards an association between the MIR196A2 genotype and DFS was also
observed; mean DFS was 115 months (95% CI, 99–131) for patients with the CC genotype, compared to 81 months (95% CI, 66–97) for those with the
CT or TT genotype (P=0.07). (D) Mean OS for 71 patients (54.2%) with the XPO5 AC genotype was 135.3 months (95% CI, 127–143) vs. 114.2 months
(95% CI, 99–129) for those with the AA or CC genotype (P= 0.033).
doi:10.1371/journal.pone.0064716.g001
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prognostic factor (HR, 2.622; 95%CI, 1.039–6.620; P= 0.041),
and we observed a trend towards significance for TRBP
(P= 0.056) (Table 4).
In the multivariate analysis for OS, only age,45 (HR, 0.004;
95%CI, 0.000–0.109; P= 0.001), anemia (HR, 11.4; 95%CI,
1.447–90.683; P= 0.021) and hypoalbuminemia (HR, 24.4;
95%CI, 1.2–480.9; P= 0.036) were independent prognostic
factors. We also observed a trend towards significance for high
LDH (P= 0.052), and XPO5 genotype (P= 0.070) (Table 4).
Discussion
Since the importance of miRNAs in tumorogenesis was first
recognized, miRNA pharmacogenomics has emerged as a
promising field [39]. The role of miR-SNPs in drug resistance,
toxicity and disease progression is becoming clearer, and miR-
SNPs are starting to be recognized as powerful tools for disease
prognosis and diagnosis [40]. In the present study, we have
analyzed the effect of eight miR-SNPs on toxicity, response, DFS
and OS in 141 adult patients diagnosed with HL and found that
miR-SNPs in XPO5 and TRBP – both individually and in
combination – are associated with clinical outcome.
This is an exploratory study of miR-SNPs in HL, and multiple
testing adjustment was not included in the original study design.
When and how multiple testing adjustment should be performed is
a controversial issue[41], and moreover, all the results presented
here should be validated in an independent set of patients.
However, in an exploratory analysis, false discovery rate adjust-
ment was applied, and all the significant clinical characteristics
shown in Table 1, as well as XPO5 in advanced-stage patients and
the XPO5/TRBP combination, maintained statistical significance.
After performing the miR-SNP analyses, we observed that
MIR423 (p = 0.031) and KRT81 (p = 0.041) showed differences in
frequency in comparison with the European population. Both of
these miR-SNPs have been reported to be related to cancer risk
when compared between normal tissue of control samples and
samples from cancer patients, and our findings support this.
Moreover, when we analyzed if the miR-SNPs analyzed were in
Hardy-Weinberg equilibrium (HWE), we found that one of them,
MIR149, was not (p,0.001). Thus, it seems that an HL
population is affected in some way and has more homozygotes
for the SNP genotype (TT) with a decreased number of
heterozygotes (CT). HWE is a mathematical construct describing
a hypothetical ideal population and natural populations can
sometimes approximate equilibrium but rarely precisely achieve it.
Figure 2. Clinical outcomes in early and advanced HL according to miR-SNPs. DFS in early-stage HL patients according to KRT81 and TRBP and in
advanced HL patients according to XPO5. And OS in advanced-stage HL patients according to XPO5. (A) DFS was 72.3 months (95% CI, 59–86) for
patients with the KRT81 CG genotype and 114.3 months (95% CI, 103–125) for those with the TT or TC genotype (P=0.037). (B) A trend towards an
association between the TRBP genotype and DFS in early-stage patients was also observed; mean DFS was 117 months (95% CI, 105–129) for patients
with the TT genotype, compared to 92 months (95% CI, 78–106) for those with the CC or TC genotype (P= 0.081). (C) All patients with the XPO5 AC
genotype were disease-free at the time of this analysis, while mean DFS among patients with the AA or CC genotype was 30.9 months (95% CI, 18–
44) (P=0.002). (D) OS was 133 months (95% CI, 118–148) in patients harboring the AC genotype compared to 74 months (95% CI, 55–94) for those
with the AA or CC genotype (P= 0.035).
doi:10.1371/journal.pone.0064716.g002
MiR-SNPs in HL
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Moreover, we have to take into account that we did not analyze
the SNPs in normal tissue, which could partially explain these
differences. Importantly, however, we have observed for the first
time in HL that patients carrying the XPO5 AC genotype had
both higher response rates and longer DFS and OS. These results
are along the lines of previous findings in non-small-cell lung
Figure 3. DFS and OS according to the combination of TRBP and XPO5 genotypes. Patients with both the XPO5 AA/CC and TRBP TT/TC genotypes
had the worst prognosis. (A) DFS was 74 months (95% CI, 54–94) for patients with the unfavorable combination, compared to 114 months (95% CI,
102–126) for those with other combinations (P= 0.008). (B) OS was 103 months (95% CI, 86–120) for patients with the unfavorable combination and
135 months (95% CI, 128–143) for those with other combinations (P= 0.008).
doi:10.1371/journal.pone.0064716.g003
Table 4. Multivariate analyses of DFS and OS.
P Hazard Ratio 95% CI
DFS
Anemia 0.441 1.4 0.5–4.2
Age,45 0.241 0.5 0.2–1.4
Advanced Stage 0.950 1.035 0.3–3.0
MIR196A2 CC 0.108 0.4 0.1–1.1
TRBP TT+TC 0.056 3.427 0.971–12.092
XPO5 AA+CC 0.041 2.622 1.039–6.620
OS
B symptoms 0.562 2.3 0.1–39.7
Nodular sclerosis subtype 0.237 0.14 0.05–3.6
Lymphocytopenia, 0.66109/L or,8% of WBC 0.468 2.1 0.3–13.9
High B-2-microglobulin level,.25 mg/L 0.299 3.6 0.3–40.2
Age,45 0.003 0.001 0.000–0.08
Anemia 0.028 14.2 1.3–151.4
Hypoalbuminemia 0.036 24.4 1.2–480.9
High LDH levels 0.052 15.2 0.98–235.7
Advanced Stage 0.246 4.382 0.4–53.2
EBV 0.642 1.7 0.2–16.5
XPO5 AA+CC 0.070 5.01 0.9–28.7
doi:10.1371/journal.pone.0064716.t004
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cancer [27], colorectal cancer [42], and multiple myeloma [29]
where the XPO5 AC genotype was associated with better
prognosis (AC+CC genotype) in NSCLC and multiple myeloma
and better treatment response (AC+AA genotype) in colorectal
cancer.
A reduced risk for patients with the heterozygous genotype
seems difficult to explain since outcomes in heterozygous patients
are usually similar to those in one of the homozygous groups (WT
or SNP). However, prognosis in HL patients is usually relatively
good, and consequently there are relatively few events. For this
reason, a large patient cohort is needed to determine which of the
homozygous groups would have as good a prognosis as the
heterozygous group. When we performed an age-adjusted analysis
(Table S3, Figure S1), we observed that in patients,45 years old,
the WT and the heterozygous groups had the best prognosis, while
in patients$45 years old, there were clear differences in prognosis
between the WT and heterozygous groups and the heterozygous
group had the best prognosis in both age groups. Nevertheless,
since this is an exploratory study, no clear conclusions can be
drawn without further study to validate our findings.
XPO5 is the RAN-GTP-dependent protein responsible for
transportation of pre-miRNA from the nucleus to the cytoplasm,
and XPO5 down-regulation results in reduced miRNA levels [43].
Mutations in XPO5 have been related to reduced miRNA
processing and decreased miRNA-target inhibition in several
tumors [44]. However, the exact role of XPO5 dysregulation is not
clear, since XPO5 is downregulated in low-grade lung adenocar-
cinoma [45] but upregulated in high-grade prostate cancer [46].
The miR-SNP rs11077 is located in the 39UTR region of the
XPO5 mRNA and may affect XPO5 protein levels. Patients
carrying the TRBP CC genotype also had longer DFS. The TRBP
rs784567 miR-SNP has previously been related to an increased
risk of bladder cancer (CC genotype) [47] and oral premalignant
lesions (TT genotype) [48]. TRBP plays its role in the cytoplasm,
where it binds to Dicer and Ago proteins to conform the RISC
complex that contributes to miRNA-mediated inhibition of
translation [49]. TRBP mutations have been described in several
tumors [50] and related to reduced TRBP protein expression and
defective processing of miRNAs.
When we investigated the combined effect of the XPO5 and
TRBP miR-SNPs, we found that patients with both the XPO5
AA/CC and TRBP TT/TC genotypes had the worst prognosis
for both DFS and OS. Both XPO5 and TRBP are key players in
miRNA biogenesis. Although XPO5 is located in the nuclear
membrane while TRBP is located in the cytoplasm, they both
interact with Dicer [51,52], a key component in the miRNA
pathway. Dicer is responsible for the cleavage of the pre-miRNA
to the miRNA/miRNA* duplex [53]. XPO5 is able to mediate the
nuclear export of Dicer mRNA [51] and TRBP is necessary for
the recruitment of Dicer to RISC [52], suggesting that miR-SNPs
in either or both of these genes may well interfere in Dicer-
mediated miRNA biogenesis.
In the present study, early-stage patients carrying the KRT81
CG genotype had shorter DFS, while advanced patients carrying
the XPO5 AC genotype had longer DFS and OS. Treatment
decisions in HL are based in large part on disease stage at the time
of diagnosis. In general, early-stage HL patients are more likely to
be cured and less likely to relapse than advanced patients.
However, relapse in early-stage patients is not uncommon [38],
and the early identification of patients more likely to relapse could
allow them to be treated with more aggressive therapies normally
reserved for advanced HL. At the same time, the identification of
good-prognosis patients with advanced HL could allow a
reduction in intensity of chemotherapy and/or radiotherapy in
these patients.
Treatment strategies in HL are often related to pulmonary and
neurologic toxicity. Bleomycin-related pulmonary toxicity has
been widely described in HL patients treated with ABVD or
MOPPABVD [54]. Suggested risk factors for pulmonary toxicity
include advanced age, bleomycin treatment, higher bleomycin
dose, renal insufficiency, radiation, underlying lung disease,
smoking history, and granulocyte colony-stimulating factor sup-
port [55]. We have shown here that the XPO5 AA or CC
genotypes are also associated with an increased risk of bleomycin-
associated pulmonary toxicity. One of the most frequent
neurologic toxicities in HL is the mixed motor-sensory neuropathy
associated with vincristine [56]. In the present study, the KRT81
GG genotype identified patients with an increased risk of
neurological toxicity. Recent advances in the understanding of
HL pathogenesis have led to the development of novel therapies
targeting the microenvironment and the specific molecular
pathways in HRS cells, including for example monoclonal
antibodies (rituximab and alemtuzumab) [57], bortezomib or
histone deacetylase inhibitors [58]. These new drugs have fewer
side effects than conventional chemotherapy, and the molecular
identification of patients at high risk of pulmonary or neurologic
toxicity could make them candidates for treatment with these new,
better-tolerated therapies.
In conclusion, miR-SNPs are a novel class of SNPs that can add
useful prognostic information on the clinical outcome of HL,
specifically in the identification of patients less likely to respond
and more likely to relapse to standard treatments and of those at
higher risk of suffering treatment-related toxicities. Importantly,
the TRBP/XPO5 haplotype has surfaced as a promising
prognostic factor that warrants further investigation to confirm
its role as a biomarker in HL.
Design and Methods
Study population and ethics statement
One hundred and forty-one adult patients diagnosed with HL at
Hospital Clinic in Barcelona, Spain between September 1995 and
June 2005 were included in the study. Patients with available
tumor samples281% of HL patients diagnosed and treated in the
center – were selected consecutively over time. The selected
patients were treated by different physicians based on the common
treatment criteria of the Hematology Department of Hospital
Clinic, Barcelona.
The clinical parameters included in this study are internation-
ally accepted as relevant in HL and are included in international
prognostic indexes [30,31]. Anemia, leukocytosis, lymphopenia,
albuminemia were determined by standard blood analyses. B
symptoms, the standard method for classifying lymphomas
according to clinical symptoms, include fever, night sweats and
weight loss of.10% of total body weight over the last 6 months.
Bulky mass is defined as.1/3 widening or mediastinum at T5-6,
or.10 cm dimension of nodal mass. B2M (beta 2 microglobulin)
was determined by immunonephelometry using reagents from
Siemens Healthcare (Germany) and automatically analyzed with
the Siemens BNII system. LDH (lactate dehydrogenase) was
analyzed with the Advia Chemistry System (Siemens). The
presence of EBV in HL lymph nodes was examined by in situ
hybridization for EBV RNA in an automated platform Bench-
Mark XT (EBER 1 and 2, Inform EBER; Ventana Medical
Systems, Tucson, AZ). Toxicities were determined according to
the Common Toxicity Criteria (CTC) of the EORTC. Approval
for the study was obtained from the Clinical Research Ethics
MiR-SNPs in HL
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Committee of the Hospital Clı´nic de Barcelona (CEIC Hospital
Clı´nic), and written informed consent was obtained from each
participant in accordance with the Declaration of Helsinki.
Selection of the miR-SNPs
In two previous studies by our group[27,29], we found that
some miR-SNPs had prognostic implications in non-small-cell
lung cancer and multiple myeloma. Based on these previous
findings, we have analyzed eight miR-SNPs in genes involved in
miRNA regulatory pathways: four in miRNA genes (MIR196A2
rs11614913; MIR149 rs2292832; MIR423 rs6505162; MIR146
rs2910164); two in miRNA binding sites in the keratin 81 (KRT81
rs3660) and family with sequence similarity 179, member B
(FAM179B rs1053667); and three in the miRNA-processing
machinery genes exportin 5 (XPO5 rs11077) and TAR RNA
binding protein 2 (TRBP rs784567). All SNPs were previously
selected according to the following criteria: firstly, a determined
allele frequency for the European population and availability in
the National Center for Biotechnology Information (NCBI) SNP
database; secondly, a genotype frequency for the European
population$0.05; and finally, either a known association with a
differential susceptibility to cancer development or clinical
outcome in other tumors. The two SNPs in miRNA binding sites
had previously been reported to have an aberrant allelic frequency
in human tumors [32]. Moreover, three of the eight SNPs have
been shown to have functional implications, as demonstrated by
our group (XPO5, KRT81)[27,29] and others (MIR196A2)[33].
DNA extraction and genotyping
DNA was obtained from formalin-fixed, paraffin-embedded
lymph nodes using the commercial DNeasy tissue kit (Qiagen,
Valencia, CA) following the manufacturer’s protocol. DNA was
quantified with a NanoDrop ND-1000 spectrophotometer
(Thermo Fisher Scientific Inc., Waltham, MA). SNP analysis
was performed by allelic discrimination on ABI Prism 7500 as
previously described [27]. Primers and probes were commercially
available (TaqMan SNP Genotyping Assays, Applied Biosystems,
Foster City, CA).
Statistical analyses
The present work is retrospective analysis of miR-SNPS in HL
patients. The analysis is based on a median follow up of 50
months. All the clinical characteristics were obtained at diagnosis.
The two primary endpoints analyzed were disease-free survival
(DFS) and overall survival (OS). DFS was measured from the time
of occurrence of a disease-free state or attainment of a complete
response (CR) to disease recurrence or death as a result of
lymphoma or acute toxicity of treatment. OS was calculated from
the time of diagnosis to the date of death or last follow-up. The
Kaplan –Meier method was used to estimate DFS and OS, and
comparison between risk groups was performed by using the log-
rank test[34,35]. A multivariate regression analysis assessing the
significance of individual clinical factors included in the Interna-
tional Score (all prognostic variables in the univariate analysis with
a P-value less than or equal to 0.2) and significant miR-SNPs was
performed by using the Cox proportional hazards model with
backward selection[36]. The proportional hazard assumption was
tested for each variable by analyzing the Schoenfeld residuals(R
software). As secondary endpoints, we analyzed the association of
miR-SNPs with treatment-related toxicities and treatment re-
sponse. The Chi-squared or Fisher’s exact test was used to estimate
differences in distributions. The multivariate analysis for toxicity
was performed by using Binary Logistic regression. All statistical
analyses were performed using PAS W Statistics 18 (SPSS Inc.,
Chicago, IL) and R software (v2.13.2). The level of significance
was set at#0.05. The statistical power of the study, calculated
using GWAPower[37], was 0.81580 with the mean sample size of
n = 125 (range 0.74561–0.85541).
Supporting Information
Figure S1 Age adjusted analysis (Age,45 and age$45).
The statistical power of the age adjusted analysis, calculated using
GWAPower, was 0.77014 for the Age,45 subgroup with the
sample size of n = 110, and it was 0.34112 for the Age$45
subgroup with the sample size of n = 31.
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Table S1 Univarite analysis of the association between
treatment-related toxicities and main clinical charac-
teristics.
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Table S2 Clinical characteristics of HL patients strat-
ified according to miRNA-SNPs. EBV status was only
available for 105 patients.
(DOCX)
Table S3 Age adjusted analysis (Age,45 and age$45).
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